aap Implantate AG Enters Joint Venture for its Reconstructive Implant Business in Greater Asian Market
(Thomson Reuters ONE) -
aap Implantate AG /
aap Implantate AG Enters Joint Venture for its Reconstructive Implant Business
in Greater Asian Market
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (XETRA: AAQ.DE) and a British Virgin Island-based Private
Equity Company ("PE Company") announced today that they have entered a joint
venture for aap's reconstructive implant business in the greater Asian market.
Under the terms of the agreement, the PE Company will acquire 67% of the shares
of aaps reconstructive implant subsidiary, aap Joints GmbH (aap Joints), for a
consideration of EUR 3 million in cash, subject to adjustments for working
capital. The notary authorization of all agreements is scheduled for July 3(rd).
aap Joints focuses on reconstructive implants (hips, knees, shoulder) and
related products, including the bone cement C~ment®. In 2012 aap Joints recorded
sales of EUR 2.2 million. This joint venture will expand sales activity into the
greater Asian market, leveraging aap's product development and manufacturing
expertise along with the local market commercial expertise of selected Asian
medtech entrepreneurs. aap Joints plans to immediately initiate registration
activities in China, and based on current expectations, aap anticipates the
joint venture will achieve its first sales in the high growth Indian and Chinese
markets in the second half of 2013 and late 2014, respectively. In addition, the
joint venture will benefit from plans to expand the product portfolio with
additional Biomaterials. Outside of the greater Asian market, aap Joints will
continue to serve its existing customer base in Europe and the Middle East.
As a result of the acquisition of shares as part of the joint venture
agreements, we expect a slightly positive EBITDA impact on aap Implantate AG's
financial results. It is expected to have a positive impact on the Company's
balance sheet given the anticipated decrease in inventory of approximately EUR
2 million, lower intangible assets (capitalized development cost) of
approximately EUR 1.5 million and a strong improvement of the net working
capital quote.
Biense Visser, CEO of aap Implantate AG, said, "This joint venture represents
another milestone in the ongoing implementation of our strategy to focus on the
key elements of our business, including trauma and biomaterials. We have been
evaluating various alternatives for our Recon portfolio and this joint venture
offers an attractive business opportunity in the strategic greater Asian market.
aap Implantate AG will benefit directly from increased supplies to aap Joints
GmbH and indirectly from the value created by this joint venture."
Isaac Bresnick, Managing Director of aap Joints GmbH, said, "The joint venture
allows us to build up a market share in the growing Asian medtech market with
recon products and cements. We will now be able to offer customers in Asia high
quality orthopaedic recon products with an excellent reputation, given that they
are made in Germany and have received U.S. and/or European regulatory approval.
The joint venture may also allow us to increase our value proposition by
outsourcing parts of the manufacturing to recognized Asian suppliers. Together
with the aap management we will select other products from aap's portfolio for
sales in China and other Asian markets."
aap Implantate AG will update its guidance for the third quarter and the full
year 2013 to include the impact of the joint venture in conjunction with the
publication of the report for the second quarter on August 14, 2013.
This release contains forward-looking statements based on current experience,
estimates and projections of the management board and currently available
information. They are not guarantees of future performance. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. Many factors could
cause the actual results, performance or achievements of aap to be materially
different from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does not
assume any obligation to update the forward-looking statements contained in this
release or to conform them to future events or developments.
______________________________________________________
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -
aap is a global medical device company headquartered in Berlin, Germany that
develops, manufactures and markets innovative biomaterials and implants that are
used in orthopedic procedures. The Company's products, which include a full line
of plating systems, cannulated screws and bone cement products, are primarily
used in the orthopedic specialty areas of trauma and spine repair. The Company's
products are sold through its direct sales force, distribution partners and
license agreements with OEM partners. aap's stock is listed in the Prime
Standard segment of the Frankfurt Stock Exchange. For more information, please
visit www.aap.de, or download the Company's investor relations app from the
Apple's App Store or Google Play.
For inquiries please contact:
aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin,
Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, m.heydrich(at)aap.de
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via Thomson Reuters ONE
[HUG#1712909]
Unternehmensinformation / Kurzprofil:
Datum: 28.06.2013 - 15:59 Uhr
Sprache: Deutsch
News-ID 274422
Anzahl Zeichen: 6942
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 263 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"aap Implantate AG Enters Joint Venture for its Reconstructive Implant Business in Greater Asian Market"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
